Greg Zante, Chief Financial Officer at Viking Therapeutics, Inc. (VKTX), sold 217,106 shares at $17.00 ($3.8M) on 2023-03-30, disclosed to the SEC on 2023-04-03.
Open-market sale of $3.8M VKTX by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $17.00 | 131,029 | $2.2M | 59.3% |
| 2 | $17.57 | 55,166 | $969K | 25.8% |
| 3 | $18.00 | 30,911 | $556K | 14.8% |
| Total | $17.29 avg | 217,106 | $3.8M | 100% |
| Filing → |
| VKTX | SELL | 2025-10-28 | $216K | — | Filing → |
| VKTX | SELL | 2025-07-03 | $237K | — | Filing → |
| VKTX | SELL | 2025-01-06 | $4.1M | — | Filing → |